Note: Impact Health Clinics welcomes all patients seeking medical weight loss, hormone optimization, and wellness care. Our services are available to everyone.
Retatrutide: The Next Generation of Weight Loss Treatment
In what can only be described as a breakthrough for the weight loss and metabolic health industry, Eli Lilly's experimental drug Retatrutide has demonstrated remarkable efficacy in Phase 3 clinical trials.
The Phase 3 Trial Results
The TRIUMPH-4 trial delivered results that exceeded even optimistic expectations:
Weight Loss Results
- Average weight loss of 28.7% in patients receiving the 12 mg dose
- This equates to approximately 71.2 pounds over 68 weeks
- Significantly outperforming semaglutide and tirzepatide
Pain Relief and Mobility
- 75.8% reduction in knee pain scores
- Over 12% became completely pain-free from knee arthritis
How Retatrutide Works
Retatrutide is a triple agonist that activates three hormone receptors:
GLP-1 (Glucagon-Like Peptide-1)
- Reduces appetite and food cravings
- Improves blood sugar control
GIP (Glucose-Dependent Insulinotropic Polypeptide)
- Enhances weight loss effects
- Reduces visceral fat
Glucagon
- Increases energy expenditure
- Enhances fat burning
Safety Profile
Common side effects include nausea, diarrhea, constipation, and vomiting. Dysesthesia was reported in 8.8-20.9% of treated patients vs 0.7% placebo.
What This Means for Health & Wellness
Retatrutide represents a significant advancement for everyone struggling with obesity. The triple-action mechanism addresses appetite, metabolism, and energy expenditure simultaneously.
Timeline and Availability
Based on Phase 3 success, FDA approval could happen within 12-18 months. Retatrutide is not yet available for prescription.
Medical Disclaimer
This article is for educational purposes only. Retatrutide is not yet FDA approved. All weight loss medications should be used under qualified healthcare provider supervision.